Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults

Current Medical Research and Opinion

Volumn 21, Issue 5, 2005, Pages 769-775

  Howard, Danny R ^a   Haribhakti, Rajiv ^a   Kittner, Barbara ^a   Agrawala, Praful ^a  

^a SANOFI   (France)

Author keywords

Bioequivalent; Combination formulation; Fexofenadine; Pharmacokinetics; Pseudoephedrine; Seasonal allergic rhinitis

Indexed keywords

FEXOFENADINE; FEXOFENADINE PLUS PSEUDOEPHEDRINE; PSEUDOEPHEDRINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; SUSTAINED DRUG RELEASE; XEROSTOMIA;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ADULT; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EPHEDRINE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; RHINITIS, ALLERGIC, PERENNIAL; TABLETS; TERFENADINE; THERAPEUTIC EQUIVALENCY;

EID: 18844402629     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X43703     Document Type: Article

References (26)

1. Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 2000;21:1-6
2. Verlato G, Corsico A, Villani S, et al. Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol 2003;111:1232-8
3. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999;20:209-13
4. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108(Suppl 1):S45-S53
5. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000;85:338-47
6. 1-antihistamine for the 21st century. Clin Exp Allergy Rev 2002;2:1-8
7. Druce H, Kaliner M. Allergic Rhinitis. J Am Med Assoc 1988;259:260-3
8. Busse W. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996;26:868-79
9. Flowers BK, Proud D, Kagey-Sobotka A, et al. The effect of a leukotriene antagonist on the early response to antigen. Otolaryngol Head Neck Surg 1990;102:219-24
10. Juniper E, Rohrbaugh T, Meltzer E. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2003;111:484-90
11. Johnson D, Hricik J. The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy 1993;13:110S-5S
12. Cantu C, Arauz A, Murillo-Bonilla L, et al. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke 2003;34:1667-72
13. Beck R, Mercado D, Seguin S, et al. Cardiovascular effects of pseudoephedrine in medically controlled hypertensive patients. Arch Intern Med 1992;152:1242-5
14. Cappell M. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175-90
15. Berkowitz R, McCafferty F, Lutz C, et al. Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. Allergy Asthma Proc 2004;25:335-43
16. Berkowitz R, Woodworth G, Lutz C, et al. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma Immunol 2002;89:38-45
17. Sussman G, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:100-6
18. Richter A, Anton S, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35
19. Horak F, Toth J, Marks B, et al. Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Allergy 1998;53:849-56
20. Schenkel E, Corren J, Murray J. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc 2002;23:325-30
21. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 1995;96:139-47
22. Stubner U, Toth J, Marks B, et al. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion. Arzneimittel-Forschung 2001;51:904-10
23. Hindmarch I. CNS effects of antihistamines: is there a third generation of non-sedative drugs? Clin Exp Allergy Rev 2002;2:26-31
24. Bertrand B, Jamart J, Marchal J, et al. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology 1996;34:91-6
25. Zyrtec-D 12 hour® (cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg extended release tablets product information package insert). New York, USA: Pfizer Inc; 2004
26. US Department of Health and Human Services. Agency for Healthcare Research and Quality. Management of allergic and nonallergic rhinitis. Summary, Evidence Report/Technology Assessment: Number 54 (2002). Available from http://www. ahrq.gov/clinic/epcsums/rhinsum.htm [accessed 2005]